Skip to main content

Table 3 Hazard ratio of treatment discontinuation in the bDMARDs-naïve cases (Fine-Gray hazard competing risk regression model, adjusted by baseline age, sex, disease duration, concomitant PSL and MTX usage, and starting date of bDMARDs)

From: Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study

  Reference HR (95% CI)
Variable ABT (n = 390) ADA (n = 374) CZP (n = 135) ETN (n = 616) GLM (n = 208) IFX (n = 650) TCZ (n = 364) P value
Lack of effectiveness 1 1.4 (1.0–2.1) 2.4 (1.5–3.8)*** 1.7 (1.2–2.4)** 1.1 (0.7–1.7) 1.5 (1.1–2.2)* 1.1 (0.8–1.7) < 0.001
All toxic adverse events 1 2.8 (1.5–5.2)*** 1.7 (0.7–4.0) 4.0 (2.3–6.9)*** 2.5 (1.3–4.8)** 4.3 (2.5–7.3)*** 2.2 (1.2–4.2)* < 0.001
Non-toxic reasons 1 0.8 (0.5–1.3) 0.3 (0.1–0.9)* 1.1 (0.7–1.6) 1.5 (0.9–2.5) 1.0 (0.7–1.5) 1.1 (0.7–1.8) 0.07
Remission 1 2.9 (1.5–5.4)*** 1.8 (0.8–4.4) 1.0 (0.5–2.0) 2.4 (1.2–5.0)* 3.1 (1.7–5.6)*** 2.5 (1.3–4.8) ** < 0.001
All adverse events (including lack of effectiveness and toxic adverse events) 1 1.8 (1.3–2.5)*** 2.5 (1.6–3.7) *** 2.3 (1.7–3.1)*** 1.5 (1.0–2.2)* 2.1 (1.6–2.9)*** 1.4 (1.0–2.0)* < 0.001
  1. bDMARDs biological disease-modifying antirheumatic drugs, PSL prednisolone, MTX methotrexate, HR hazard ratio, 95% CI 95% confidence interval, ABT abatacept, ADA adalimumab, CZP certolizumab pegol, ETN etanercept, GLM golimumab, IFX infliximab, TCZ tocilizumab
  2. *P < 0.05, **P < 0.01, ***P < 0.001